Scott Power: Which stock fell off its perch on poor trial results this week?
Percheron shares tumbled on negative Duchenne muscular dystrophy phase 2b trial results this week EBR Systems edged closer to FDA approval for WiSE with a manufacturing pre-approval inspection in early January ASX health stocks fell 1% over past five days, …